Last reviewed · How we verify

Multiple Sclerosis Center of Northeastern New York — Portfolio Competitive Intelligence Brief

Multiple Sclerosis Center of Northeastern New York pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
BG00012 (DMF) (Tecfidera®.) BG00012 (DMF) (Tecfidera®.) marketed Fumaric acid ester; Nrf2 activator Nuclear factor erythroid 2-related factor 2 (Nrf2) Neurology; Immunology
incabotulinumtoxinA incabotulinumtoxinA marketed Botulinum toxin type A SNARE complex (synaptobrevin/VAMP) Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ATGC Co., Ltd. · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Brigitte Schürch · 1 shared drug class
  4. Carruthers Dermatology Centre · 1 shared drug class
  5. Department of Medical Services Ministry of Public Health of Thailand · 1 shared drug class
  6. Galderma R&D · 1 shared drug class
  7. Huons Co., Ltd. · 1 shared drug class
  8. Innovaderm Research Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Multiple Sclerosis Center of Northeastern New York:

Cite this brief

Drug Landscape (2026). Multiple Sclerosis Center of Northeastern New York — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/multiple-sclerosis-center-of-northeastern-new-york. Accessed 2026-05-17.

Related